查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1951158

基因合成市場－全球產業規模、佔有率、趨勢、機會、預測（按方法、服務、應用、最終用途、地區和競爭格局分類，2021-2031年）

Gene Synthesis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, By Method, By Service, By Application, By End Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球基因合成市場預計將從 2025 年的 21.1 億美元成長到 2031 年的 37.3 億美元，複合年成長率為 9.96%。

基因合成是指不依賴天然模板，從頭建構雙股DNA序列的化學方法，它能夠精確地建構複雜的基因和基因組，用於生物學研究。這一成長主要受以下因素驅動：對個人化治療策略日益成長的需求、疫苗快速研發的迫切需要，以及生命科學領域為支持研發活動而注入的大量資金。 SynBioBeta的報告也印證了這項資金復甦的趨勢：到2024年，合成生物學領域的創投將達到122億美元，顯示強勁的資金籌措水準對於維持產業擴張和加速技術突破至關重要。

市場概覽
預測期 2027-2031
市場規模：2025年 21.1億美元
市場規模：2031年 37.3億美元
複合年成長率：2026-2031年 9.96%
成長最快的細分市場 固相合成
最大的市場 北美洲

儘管前景樂觀，但合成DNA潛在的濫用所帶來的生物安全風險，仍構成市場面臨的重大障礙。對意外或惡意製造危險病原體的擔憂，迫使各國政府和國際組織實施嚴格的法規結構和篩檢程序。這些強制性合規措施給製造商帶來了高昂的營運成本和沈重的行政負擔，可能導致生產延誤，並阻礙全球基因合成市場的更廣泛應用。

市場促進因素

高通量DNA合成技術的進步正顯著加速合成生物學在工業和科研領域的應用。矽基和酶促合成技術的進步使得複雜、高精度基因序列的快速、大規模生產成為可能，從根本上打破了傳統設計-構建-測試-學習循環的限制。這種擴充性使得商業供應商能夠滿足日益成長的需求，因為越來越多的研究人員將突變體庫和代謝途徑的建構外包出去。例如，Twist Biosciences在其2024年11月發布的「2024會計年度第四季及全年」財務報告中披露，該公司在該會計年度交付了約77.2萬個基因。與上一時期相比，這顯示可擴展合成技術的應用顯著增加。

此外，基因和細胞療法臨床開發平臺的不斷擴展正在推動市場發展，從而持續催生對GMP級合成DNA的需求，而合成DNA對於病毒載體生產和mRNA治療模板至關重要。隨著製藥公司推進候選藥物從發現階段進入受監管的臨床試驗，對精準遺傳物質的需求也穩定成長，以確保治療的安全性和有效性。根據美國基因和細胞治療學會（ASGCT）於2024年4月發布的《2024年第一季基因、細胞和RNA療法現況報告》，全球基因、細胞和RNA治療方法開發平臺已擴展至4016種，凸顯了對原料的龐大需求。為了支持這一成長，新參與企業正利用投資者的興趣擴大其生產能力。例如，Elegen在2024年完成了3,500萬美元的B輪資金籌措，用於將其專有的無細胞DNA生產基礎設施商業化。

市場挑戰

全球基因合成市場面臨源自生物安全威脅的重大挑戰，這些威脅與合成DNA潛在的濫用有關。對危險病原體設計的擔憂促使人們實施嚴格的法律規範和篩檢通訊協定。這些合規要求迫使製造商在其工作流程中加入昂貴且耗時的檢驗系統，從而直接增加營運成本並延長產品交付時間。

這些安全措施的負擔對市場的柔軟性和擴充性造成了不成比例的影響。企業不得不將大量資源投入政府的審查程序和「了解你的客戶」（KYC）檢驗中，而不是專注於生產速度和創新。正如國際基因合成聯盟在2024年指出的那樣，超過40家領先的基因合成供應商已承諾遵守統一的篩檢通訊協定，以符合這些嚴格的生物安全標準。雖然這種廣泛的合規性對於確保公共至關重要，但程序上的複雜性阻礙了生產效率，並限制了整個基因合成產業的成長潛力。

市場趨勢

DNA資料儲存是一項新興應用，它透過解決傳統數位存檔的嚴重局限性，正在改變市場格局。隨著全球數據生成量超過磁性及矽基儲存介質的容量，合成DNA憑藉其卓越的體積密度和耐久性，成為儲存數千年資訊的理想替代方案。該應用需要合成大量的編碼寡核苷酸，這為基因合成供應商創造了一條新的、利潤豐厚的收入來源，而不僅限於生物研究的需求。例如，在2025年5月題為「DNA資料儲存業務分拆為獨立公司」的新聞稿中，Twist Biosciences宣布已為其新成立的子公司Atlas Data Storage籌集了1.55億美元的種子資金，旨在將這項存檔技術推向市場，並滿足日益成長的長期資料儲存需求。

分散式桌上型DNA列印平台的廣泛應用正推動著服務模式從集中式轉變為現場生產的根本性轉變。實驗室擴大部署自動化合成設備，在現場生產遺傳物質，消除運輸延誤，並降低外包帶來的智慧財產權風險。這種轉變使研究人員能夠快速迭代設計，縮短疫苗開發和代謝工程計劃的周期，而無需依賴外部供應商。根據2025年3月發布的公告“Telesis Bio從Novalis Life Sciences和Northpond Ventures融資2100萬美元”，Telesis Bio獲得這筆資金的目的是加速其自動化台式合成系統的商業化部署，這凸顯了該行業向分佈式生產能力的戰略轉型。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球基因合成市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依方法（固相合成、晶片合成、PCR酶合成）
    • 依服務項目（抗體DNA合成、病毒DNA合成等）
    • 按應用領域（基因/細胞療法開發、疫苗開發、疾病診斷等）
    • 依最終用戶（生技/製藥公司、學術/政府研究機構、受託研究機構）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美基因合成市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲基因合成市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區基因合成市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲基因合成市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲基因合成市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球基因合成市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • OriGene Technologies, Inc.
  • Integrated DNA Technologies, Inc.
  • ProMab Biotechnologies, Inc.
  • Thermo Fisher Scientific, Inc.
  • ProteoGenix, Inc.
  • Biomatik USA LLC
  • Twist Bioscience Corp.
  • Boster Biological Technology Inc.
  • Brooks Automation, Inc.
  • Genscript Corporation

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 18710

The Global Gene Synthesis Market is projected to expand from USD 2.11 Billion in 2025 to USD 3.73 Billion by 2031, registering a compound annual growth rate of 9.96%. Gene synthesis entails the de novo chemical engineering of double-stranded DNA sequences independent of natural templates, facilitating the precise creation of complex genes and genomes for biological investigation. This growth is largely fueled by the rising demand for personalized therapeutic strategies, the urgent requirement for rapid vaccine formulation, and substantial capital injections into the life sciences domain that support research and development activities. Highlighting this financial resurgence, SynBioBeta reported that venture investment in the synthetic biology sector hit $12.2 billion in 2024, indicating robust funding levels essential for sustaining industrial expansion and fostering technological breakthroughs.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.11 Billion
Market Size 2031USD 3.73 Billion
CAGR 2026-20319.96%
Fastest Growing SegmentSolid-phase Synthesis
Largest MarketNorth America

Despite this favorable outlook, the market encounters substantial hurdles related to biosecurity risks linked to the potential exploitation of synthetic DNA. Anxieties regarding the accidental or malicious generation of dangerous pathogens have compelled governments and international organizations to enforce strict regulatory frameworks and screening procedures. These mandatory compliance measures impose higher operational expenses and significant administrative loads on manufacturers, leading to potential production delays and hindering the broader proliferation of the global gene synthesis market.

Market Driver

Improvements in high-throughput DNA synthesis technologies are markedly speeding up the integration of synthetic biology into both industrial and research environments. Advances in silicon-based and enzymatic synthesis enable the large-scale production of complex, high-fidelity gene sequences with faster turnaround times, effectively eliminating past constraints in the design-build-test-learn cycle. This operational scalability permits commercial suppliers to satisfy the growing volume demands of researchers who are increasingly outsourcing the creation of variant libraries and metabolic pathways. For instance, Twist Bioscience revealed in its "Twist Bioscience Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results" from November 2024 that it shipped roughly 772,000 genes over the fiscal year, signaling a significant rise in the adoption of scalable synthesis technologies compared to previous periods.

The market is further bolstered by the broadening clinical development pipelines for gene and cell therapies, which generate a continuous demand for GMP-grade synthetic DNA essential for viral vector production and mRNA therapeutic templates. As pharmaceutical entities progress candidates from discovery stages to regulated clinical trials, the need for exact genetic materials to guarantee therapeutic safety and efficacy grows steadily. According to the "Gene, Cell, & RNA Therapy Landscape: Q1 2024 Quarterly Report" by the American Society of Gene + Cell Therapy in April 2024, the global pipeline has swelled to encompass 4,016 gene, cell, and RNA therapies, highlighting the immense raw material requirements. To support this growth, new market players are leveraging investor interest to expand manufacturing capabilities; for example, Elegen raised $35 million in Series B financing in 2024 to commercialize its proprietary cell-free DNA manufacturing infrastructure.

Market Challenge

The global gene synthesis market faces considerable obstacles arising from biosecurity threats linked to the possible misuse of synthetic DNA. Worries over the engineering of hazardous pathogens have mandated the implementation of rigorous regulatory structures and screening protocols. These compliance requirements compel manufacturers to incorporate expensive and time-intensive verification systems into their workflows, which directly elevates operational overhead and prolongs product delivery schedules.

The weight of these security precautions disproportionately impacts market flexibility and scalability. Firms are required to dedicate significant resources to administrative vetting procedures and "Know Your Customer" verifications instead of focusing solely on production velocity or technological innovation. As noted by the International Gene Synthesis Consortium in 2024, over 40 leading gene synthesis providers have pledged adherence to the Harmonized Screening Protocol to comply with these stringent biosecurity norms. While such widespread compliance is essential for ensuring public safety, the consequent rise in procedural intricacy serves as a hindrance to manufacturing efficiency, thereby curbing the overall growth potential of the gene synthesis industry.

Market Trends

The rise of DNA data storage as a new application vertical is transforming the market by tackling the severe constraints of conventional digital archiving. With global data generation exceeding the capabilities of magnetic and silicon-based storage media, synthetic DNA presents an alternative boasting superior volumetric density and durability, capable of preserving information for thousands of years. This application necessitates the synthesis of immense volumes of coding oligonucleotides, generating a fresh high-volume revenue source for gene synthesis providers separate from biological research requirements. For example, Twist Bioscience announced in a May 2025 press release titled "Twist Bioscience Spins Out DNA Data Storage as Independent Company" that it had obtained $155 million in seed funding for its new subsidiary, Atlas Data Storage, to bring this archival technology to market and address the rising demand for long-term data preservation.

A fundamental shift from centralized service models to on-site manufacturing is being driven by the adoption of decentralized benchtop DNA printing platforms. Laboratories are increasingly incorporating automated synthesizers to manufacture genetic material within their own facilities, thereby removing shipping delays and reducing intellectual property risks linked to outsourcing. This change enables researchers to iterate designs swiftly, shortening development timelines for vaccines and metabolic engineering initiatives without dependence on external suppliers. According to a March 2025 announcement titled "Telesis Bio Raises $21 Million from Novalis LifeSciences and Northpond Ventures," Telesis Bio secured this funding specifically to hasten the commercial rollout of its automated benchtop synthesis systems, emphasizing the industry's strategic move toward distributed manufacturing capabilities.

Key Market Players

  • OriGene Technologies, Inc.
  • Integrated DNA Technologies, Inc.
  • ProMab Biotechnologies, Inc.
  • Thermo Fisher Scientific, Inc.
  • ProteoGenix, Inc.
  • Biomatik USA LLC
  • Twist Bioscience Corp.
  • Boster Biological Technology Inc.
  • Brooks Automation, Inc.
  • Genscript Corporation

Report Scope

In this report, the Global Gene Synthesis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gene Synthesis Market, By Method

  • Solid-phase Synthesis
  • Chip-based Synthesis
  • PCR-based Enzyme Synthesis

Gene Synthesis Market, By Service

  • Antibody DNA Synthesis
  • Viral DNA Synthesis
  • Others

Gene Synthesis Market, By Application

  • Gene & Cell Therapy Development
  • Vaccine Development
  • Disease Diagnosis
  • Others

Gene Synthesis Market, By End Use

  • Biotechnology and Pharmaceutical Companies
  • Academic and Government Research Institutes
  • Contract Research Organizations

Gene Synthesis Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gene Synthesis Market.

Available Customizations:

Global Gene Synthesis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Gene Synthesis Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Method (Solid-phase Synthesis, Chip-based Synthesis, PCR-based Enzyme Synthesis)
    • 5.2.2. By Service (Antibody DNA Synthesis, Viral DNA Synthesis, Others)
    • 5.2.3. By Application (Gene & Cell Therapy Development, Vaccine Development, Disease Diagnosis, Others)
    • 5.2.4. By End Use (Biotechnology and Pharmaceutical Companies, Academic and Government Research Institutes, Contract Research Organizations)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Gene Synthesis Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Method
    • 6.2.2. By Service
    • 6.2.3. By Application
    • 6.2.4. By End Use
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Gene Synthesis Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Method
        • 6.3.1.2.2. By Service
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End Use
    • 6.3.2. Canada Gene Synthesis Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Method
        • 6.3.2.2.2. By Service
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End Use
    • 6.3.3. Mexico Gene Synthesis Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Method
        • 6.3.3.2.2. By Service
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End Use

7. Europe Gene Synthesis Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Method
    • 7.2.2. By Service
    • 7.2.3. By Application
    • 7.2.4. By End Use
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Gene Synthesis Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Method
        • 7.3.1.2.2. By Service
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End Use
    • 7.3.2. France Gene Synthesis Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Method
        • 7.3.2.2.2. By Service
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End Use
    • 7.3.3. United Kingdom Gene Synthesis Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Method
        • 7.3.3.2.2. By Service
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End Use
    • 7.3.4. Italy Gene Synthesis Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Method
        • 7.3.4.2.2. By Service
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End Use
    • 7.3.5. Spain Gene Synthesis Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Method
        • 7.3.5.2.2. By Service
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End Use

8. Asia Pacific Gene Synthesis Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Method
    • 8.2.2. By Service
    • 8.2.3. By Application
    • 8.2.4. By End Use
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Gene Synthesis Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Method
        • 8.3.1.2.2. By Service
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End Use
    • 8.3.2. India Gene Synthesis Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Method
        • 8.3.2.2.2. By Service
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End Use
    • 8.3.3. Japan Gene Synthesis Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Method
        • 8.3.3.2.2. By Service
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End Use
    • 8.3.4. South Korea Gene Synthesis Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Method
        • 8.3.4.2.2. By Service
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End Use
    • 8.3.5. Australia Gene Synthesis Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Method
        • 8.3.5.2.2. By Service
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End Use

9. Middle East & Africa Gene Synthesis Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Method
    • 9.2.2. By Service
    • 9.2.3. By Application
    • 9.2.4. By End Use
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Gene Synthesis Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Method
        • 9.3.1.2.2. By Service
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End Use
    • 9.3.2. UAE Gene Synthesis Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Method
        • 9.3.2.2.2. By Service
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End Use
    • 9.3.3. South Africa Gene Synthesis Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Method
        • 9.3.3.2.2. By Service
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End Use

10. South America Gene Synthesis Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Method
    • 10.2.2. By Service
    • 10.2.3. By Application
    • 10.2.4. By End Use
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Gene Synthesis Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Method
        • 10.3.1.2.2. By Service
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End Use
    • 10.3.2. Colombia Gene Synthesis Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Method
        • 10.3.2.2.2. By Service
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End Use
    • 10.3.3. Argentina Gene Synthesis Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Method
        • 10.3.3.2.2. By Service
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Gene Synthesis Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. OriGene Technologies, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Integrated DNA Technologies, Inc.
  • 15.3. ProMab Biotechnologies, Inc.
  • 15.4. Thermo Fisher Scientific, Inc.
  • 15.5. ProteoGenix, Inc.
  • 15.6. Biomatik USA LLC
  • 15.7. Twist Bioscience Corp.
  • 15.8. Boster Biological Technology Inc.
  • 15.9. Brooks Automation, Inc.
  • 15.10. Genscript Corporation

16. Strategic Recommendations

17. About Us & Disclaimer